A naphthalimide derivative exerts potent antiplatelet and antithrombotic activities without a bleeding tendency
These findings indicate that compound <b>6</b> can selectively inhibit GPVI, eventually suppressing platelet activation and thrombus formation while preserving hemostasis. Compound <b>6</b> is a GPVI antagonist and safe antiplatelet agent. Compound <b>6</b> also has therapeutic potential for treating cardiovascular diseases.
Authors
- Hsien‐Yu Peng (ORCID: https://orcid.org/0000-0002-9471-8130)
- Wan‐Jung Lu (ORCID: https://orcid.org/0000-0001-7664-4740)
- Jen‐Wei Liu
- Jiun-Yi Li
- Ray‐Jade Chen (ORCID: https://orcid.org/0000-0002-4666-6364)
- Kuan‐Hung Lin (ORCID: https://orcid.org/0000-0003-1519-1797)
- Hsueh-Hsiao Wang (ORCID: https://orcid.org/0000-0002-3100-0121)
- Tzenge‐Lien Shih (ORCID: https://orcid.org/0000-0001-5378-0782)
- Ting‐Yu Chen (ORCID: https://orcid.org/0000-0002-3445-9907)
- Wei‐Ting Kao
Institutions
- Tamkang University (TW)
- Taipei Medical University Hospital (TW)
- Mackay Memorial Hospital (TW)
- Mackay Medical University (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-24
- DOI
- https://doi.org/10.3389/fphar.2025.1541255
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Mackay Medical College
- National Science and Technology Council